No Data
No Data
Mayinglong Pharmaceutical Group (600993.SH) plans to distribute a dividend of 0.4 yuan per share for the 2023 fiscal year, with ex-dividend on July 26th.
Mayinglong Pharmaceutical Group (600993.SH) announced that it plans to distribute a cash dividend of 0.4 yuan per share for the year 2023.
Mayinglong Pharmaceutical Group (600993.SH): Di Kua Linsuo Sodium Eye Drops Obtains Pharmaceutical Registration Certificate
Mayinglong Pharmaceutical Group (600993.SH) announced that its wholly-owned subsidiary, Jiangxi Mayinglong Meikang Pharmaceutical Co., Ltd., has received the Drug Registration Certificate approved and issued by the National Medical Products Administration for Diquafosol Sodium Eye Drops. Diquafosol Sodium Eye Drops are suitable for dry eye patients diagnosed with corneal epithelial injury caused by abnormal tear fluid, which was first approved for marketing in Japan in 2010 and for importation of original research in China in 2017.
We Think Mayinglong Pharmaceutical Group (SHSE:600993) Can Manage Its Debt With Ease
Howard Marks put it nicely when he said that, rather than worrying about share price volatility, 'The possibility of permanent loss is the risk I worry about... and every practical investor I know wor
Mayinglong Pharmaceutical Group Co., Ltd. (SHSE:600993) Stock Rockets 26% As Investors Are Less Pessimistic Than Expected
Mayinglong Pharmaceutical Group Co., Ltd. (SHSE:600993) shareholders have had their patience rewarded with a 26% share price jump in the last month. Looking further back, the 11% rise over the last
Ma Yinglong (600993.SH): Net profit of 198 million yuan in the first quarter increased 5.36% year over year
Gelonghui, April 19: Ma Yinglong (600993.SH) released its report for the first quarter of 2024. During the reporting period, it achieved operating income of 955 million yuan, an increase of 14.70%; net profit attributable to shareholders of listed companies was 198 million yuan, an increase of 5.36% year on year; net profit attributable to shareholders of listed companies after deducting non-recurring profit and loss was 193 million yuan, an increase of 35.67% year on year; and basic earnings per share were 0.46 yuan.
Mayinglong Pharmaceutical Receives Registration Approval for New Colorectal Treatment
Mayinglong Pharmaceutical Group (SHA:600993) has obtained a drug registration certificate from China's National Medical Products Administration to register its new colorectal treatment, according to a
No Data